×
QQQ   283.51 (+0.49%)
AAPL   139.92 (+0.71%)
MSFT   259.70 (+0.05%)
META   164.89 (+3.04%)
GOOGL   2,232.42 (+2.65%)
AMZN   112.81 (+2.97%)
TSLA   688.89 (+1.04%)
NVDA   148.17 (+2.02%)
NIO   21.71 (+1.64%)
BABA   116.70 (+0.60%)
AMD   74.34 (+0.91%)
MU   55.89 (+4.18%)
CGC   2.64 (-6.05%)
T   20.95 (-1.69%)
GE   61.19 (-3.70%)
F   11.05 (-2.39%)
DIS   95.94 (-0.21%)
AMC   12.70 (-6.13%)
PFE   50.95 (-2.60%)
PYPL   73.51 (+2.96%)
NFLX   183.21 (+1.81%)
QQQ   283.51 (+0.49%)
AAPL   139.92 (+0.71%)
MSFT   259.70 (+0.05%)
META   164.89 (+3.04%)
GOOGL   2,232.42 (+2.65%)
AMZN   112.81 (+2.97%)
TSLA   688.89 (+1.04%)
NVDA   148.17 (+2.02%)
NIO   21.71 (+1.64%)
BABA   116.70 (+0.60%)
AMD   74.34 (+0.91%)
MU   55.89 (+4.18%)
CGC   2.64 (-6.05%)
T   20.95 (-1.69%)
GE   61.19 (-3.70%)
F   11.05 (-2.39%)
DIS   95.94 (-0.21%)
AMC   12.70 (-6.13%)
PFE   50.95 (-2.60%)
PYPL   73.51 (+2.96%)
NFLX   183.21 (+1.81%)
QQQ   283.51 (+0.49%)
AAPL   139.92 (+0.71%)
MSFT   259.70 (+0.05%)
META   164.89 (+3.04%)
GOOGL   2,232.42 (+2.65%)
AMZN   112.81 (+2.97%)
TSLA   688.89 (+1.04%)
NVDA   148.17 (+2.02%)
NIO   21.71 (+1.64%)
BABA   116.70 (+0.60%)
AMD   74.34 (+0.91%)
MU   55.89 (+4.18%)
CGC   2.64 (-6.05%)
T   20.95 (-1.69%)
GE   61.19 (-3.70%)
F   11.05 (-2.39%)
DIS   95.94 (-0.21%)
AMC   12.70 (-6.13%)
PFE   50.95 (-2.60%)
PYPL   73.51 (+2.96%)
NFLX   183.21 (+1.81%)
QQQ   283.51 (+0.49%)
AAPL   139.92 (+0.71%)
MSFT   259.70 (+0.05%)
META   164.89 (+3.04%)
GOOGL   2,232.42 (+2.65%)
AMZN   112.81 (+2.97%)
TSLA   688.89 (+1.04%)
NVDA   148.17 (+2.02%)
NIO   21.71 (+1.64%)
BABA   116.70 (+0.60%)
AMD   74.34 (+0.91%)
MU   55.89 (+4.18%)
CGC   2.64 (-6.05%)
T   20.95 (-1.69%)
GE   61.19 (-3.70%)
F   11.05 (-2.39%)
DIS   95.94 (-0.21%)
AMC   12.70 (-6.13%)
PFE   50.95 (-2.60%)
PYPL   73.51 (+2.96%)
NFLX   183.21 (+1.81%)
NASDAQ:NVAX

Novavax Stock Forecast, Price & News

$61.26
+4.11 (+7.19%)
(As of 07/5/2022 01:51 PM ET)
Add
Compare
Today's Range
$55.74
$62.40
50-Day Range
$36.28
$62.73
52-Week Range
$34.88
$277.80
Volume
134,817 shs
Average Volume
7.11 million shs
Market Capitalization
$4.79 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$164.00

Novavax MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
171.8% Upside
$164.00 Price Target
Short Interest
Healthy
20.13% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.27
Upright™ Environmental Score
News Sentiment
0.32mentions of Novavax in the last 14 days
Based on 16 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
-61.70%
From $27.23 to $10.43 Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.19 out of 5 stars

Medical Sector

293rd out of 1,428 stocks

Biological Products, Except Diagnostic Industry

44th out of 218 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive NVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novavax and its competitors with MarketBeat's FREE daily newsletter.

Novavax logo

About Novavax (NASDAQ:NVAX) Stock

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

NVAX Stock News Headlines

Why Is Novavax (NVAX) Stock Rallying Today?
What to Know About Novavax
Why Is Novavax (NVAX) Stock Up 10% Today?
Novavax (NASDAQ:NVAX) Shares Up 3.2%
2 Risky Stocks That Could Continue Falling This Year
3 Reasons to Buy Novavax and 1 to Sell
What Is Novavax? - CNET
Novavax (NASDAQ:NVAX) Trading Up 3.9%
Why Novavax Stock Is Soaring This Week
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:NVAX
CUSIP
67000210
Employees
1,541
Year Founded
1987

Company Calendar

Last Earnings
5/09/2022
Today
7/05/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$164.00
High Stock Price Forecast
$209.00
Low Stock Price Forecast
$35.00
Forecasted Upside/Downside
+167.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.5
Research Coverage
8 Analysts

Profitability

Net Income
$-1,743,750,000.00
Pretax Margin
-91.86%

Debt

Sales & Book Value

Annual Sales
$1.15 billion
Book Value
($4.65) per share

Miscellaneous

Free Float
76,494,000
Market Cap
$4.79 billion
Optionable
Optionable
Beta
1.59

Social Links















Novavax Frequently Asked Questions

Should I buy or sell Novavax stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Novavax stock.
View analyst ratings for Novavax
or view top-rated stocks.

What is Novavax's stock price forecast for 2022?

8 brokers have issued 1-year price objectives for Novavax's stock. Their NVAX stock forecasts range from $35.00 to $209.00. On average, they predict Novavax's stock price to reach $164.00 in the next twelve months. This suggests a possible upside of 170.7% from the stock's current price.
View analysts' price targets for Novavax
or view top-rated stocks among Wall Street analysts.

How has Novavax's stock performed in 2022?

Novavax's stock was trading at $143.07 at the beginning of 2022. Since then, NVAX stock has decreased by 57.7% and is now trading at $60.59.
View the best growth stocks for 2022 here
.

When is Novavax's next earnings date?

Novavax is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Novavax
.

How were Novavax's earnings last quarter?

Novavax, Inc. (NASDAQ:NVAX) issued its quarterly earnings results on Monday, May, 9th. The biopharmaceutical company reported $2.56 EPS for the quarter, missing analysts' consensus estimates of $3.33 by $0.77. The biopharmaceutical company had revenue of $703.97 million for the quarter, compared to the consensus estimate of $845.20 million. Novavax had a negative net margin of 93.91% and a negative trailing twelve-month return on equity of 572.54%. The firm's revenue for the quarter was up 57.4% on a year-over-year basis. During the same quarter last year, the company earned ($3.05) earnings per share.
View Novavax's earnings history
.

When did Novavax's stock split? How did Novavax's stock split work?

Novavax shares reverse split on Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 9th 2019. An investor that had 100 shares of Novavax stock prior to the reverse split would have 5 shares after the split.

What guidance has Novavax issued on next quarter's earnings?

Novavax issued an update on its FY 2022 earnings guidance on Monday, June, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $4.00 billion-$5.00 billion, compared to the consensus revenue estimate of $4.49 billion.

Who are Novavax's key executives?

Novavax's management team includes the following people:
  • Mr. Stanley Charles Erck, Pres, CEO & Director (Age 74, Pay $1.12M)
  • Mr. James Patrick Kelly C.F.A., Exec. VP, CFO & Treasurer (Age 56, Pay $355.23k)
  • Mr. John A. Herrmann III, Exec. VP, Chief Legal Officer & Corp. Sec. (Age 56, Pay $657.8k) (LinkedIn Profile)
  • Mr. John Joseph Trizzino B.S., M.B.A., Exec. VP and Chief Bus. & Commercial Officer (Age 62, Pay $636.85k)
  • Dr. Gregory M. Glenn, Pres of R&D (Age 68, Pay $813.44k) (LinkedIn Profile)
  • Mr. Richard P. Crowley, Exec. VP & COO (Age 65)
  • Dr. Gale E. Smith, Sr. VP of Discovery & Pre-Clinical Research and Chief Scientist (Age 72)
  • Mr. Biegie Lee, Sr. VP & Chief Information Officer
  • Ms. Silvia Taylor M.B.A., MBA, Sr. VP of Global Corp. Affairs & Investor Relations
  • Mr. Troy Morgan Esq., J.D., Sr. VP & Chief Compliance Officer (Age 51)

What is Stanley C. Erck's approval rating as Novavax's CEO?

46 employees have rated Novavax CEO Stanley C. Erck on Glassdoor.com. Stanley C. Erck has an approval rating of 71% among Novavax's employees.

What other stocks do shareholders of Novavax own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Moderna (MRNA), NVIDIA (NVDA), Tesla (TSLA), Palo Alto Networks (PANW), Advanced Micro Devices (AMD), Egalet (EGLT), Exact Sciences (EXAS) and Pfizer (PFE).

What is Novavax's stock symbol?

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

How do I buy shares of Novavax?

Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novavax's stock price today?

One share of NVAX stock can currently be purchased for approximately $60.59.

How much money does Novavax make?

Novavax (NASDAQ:NVAX) has a market capitalization of $4.73 billion and generates $1.15 billion in revenue each year. The biopharmaceutical company earns $-1,743,750,000.00 in net income (profit) each year or ($17.68) on an earnings per share basis.

How many employees does Novavax have?

Novavax employs 1,541 workers across the globe.

When was Novavax founded?

Novavax was founded in 1987.

How can I contact Novavax?

Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The official website for Novavax is www.novavax.com. The biopharmaceutical company can be reached via phone at (240) 268-2000, via email at ir@novavax.com, or via fax at 240-268-2100.

This page (NASDAQ:NVAX) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.